Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]
Immunotargets Ther
.
2023 May 25:12:77-78.
doi: 10.2147/ITT.S421440.
eCollection 2023.
Authors
Simmi Wiggins
#
1
,
Noah A Levit
#
2
Affiliations
1
Sanofi, 410 Thames Valley Park Dr, Reading, RG6 1PT, UK.
2
Regeneron Pharmaceuticals Inc, Tarrytown, NY, 10591, USA.
#
Contributed equally.
PMID:
37256021
PMCID:
PMC10226537
DOI:
10.2147/ITT.S421440
No abstract available